Business Context and Reporting Period
This Form 8-K is a current report filed by Virios Therapeutics, Inc. (not Dogwood Therapeutics, Inc., as indicated in the metadata) on November 14, 2022. The filing serves to announce the results of operations for the third quarter ended September 30, 2022. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol VIRI.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not detailed in the body of this 8-K document.
Material Changes
No material changes or comparative financial data are disclosed in the text of this filing. The document solely references the issuance of the Q3 2022 press release.
Guidance, Outlook, and Risks
The filing includes a standard disclaimer stating that the information furnished pursuant to Item 2.02, including the press release, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934. Consequently, it is not subject to the liabilities of that section and shall not be deemed incorporated by reference into any other filings under the Securities Act or Exchange Act. No specific guidance, outlook, or risk factors are detailed in this text.
Investor Verification Checklist
- Verify the correct registrant name is Virios Therapeutics, Inc., not Dogwood Therapeutics, Inc.
- Review Exhibit 99.1 (the press release) for actual Q3 2022 financial figures, as they are absent from the 8-K summary text.
- Confirm the trading symbol VIRI on the Nasdaq Capital Market.
- Note that the financial data in the referenced press release is furnished, not filed, and carries different liability implications.